Actavis extends offers to guarantee Forest Lab notes for acquisition

By Susanna Moon

Chicago, June 9 – Actavis plc said it extended its offer to guarantee three series of notes issued by Forest Laboratories, Inc.

The consent solicitations will now end at 5 p.m. ET on June 12, extended from 5 p.m. ET on June 6. The solicitations began on May 22.

The company is offering to guarantee the $1.05 billion 4 3/8% senior notes due 2019, $750 million 4 7/8% senior notes due 2021 and $1.2 billion 5% senior notes due 2021.

As of Monday, holders of a majority of each series of notes had delivered consents under the solicitations, according to a press release.

As previously announced, Actavis is offering to guarantee the notes issued by issued by Forest Laboratories in exchange for eliminating registration rights obligations for those notes.

The offer is related to the company’s pending acquisition of Forest Laboratories.

D.F. King & Co., Inc. (212 269-5550, 800 967-4617 or frx@dfking.com) is the information and tabulation agent.

Actavis is a pharmaceutical company with headquarters in Dublin. Forest Laboratories is a New York-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.